BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $95.00 at Oppenheimer

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target trimmed by Oppenheimer from $98.00 to $95.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. HC Wainwright upped their price objective on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, December 22nd. Wells Fargo & Company increased their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Wedbush reissued an “outperform” rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Morgan Stanley lowered their price target on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Fifteen analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $88.33.

BioMarin Pharmaceutical Trading Down 0.5%

BMRN opened at $62.62 on Tuesday. The stock has a market capitalization of $12.03 billion, a PE ratio of 35.18, a P/E/G ratio of 0.68 and a beta of 0.26. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. BioMarin Pharmaceutical has a 12-month low of $50.76 and a 12-month high of $73.51. The firm’s fifty day moving average price is $58.53 and its 200 day moving average price is $56.08.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Activest Wealth Management bought a new stake in BioMarin Pharmaceutical during the fourth quarter worth approximately $26,000. Quent Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter valued at $28,000. CIBC Private Wealth Group LLC lifted its position in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 360 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical in the 3rd quarter worth $40,000. 98.71% of the stock is currently owned by institutional investors.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Reported solid top-line growth: Q4 revenue rose ~17% YoY and full‑year 2025 revenue was up ~13% to $3.2B, driven by VOXZOGO and enzyme therapies; management also announced a definitive agreement to acquire Amicus, which would add marketed products (Galafold, Pombiliti + Opfolda) and diversify revenue. BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
• Positive Sentiment: Analysts remain constructive: TD Cowen maintained a Buy and a $120 PT citing the Amicus deal and multi‑year outlook; Bank of America reiterated Buy (PT $97) highlighting pipeline upside despite competitive headwinds. BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating BioMarin: Competitive Voxzogo Headwinds Offset by Pipeline Upside and Undervalued Long‑Term Growth Potential
• Neutral Sentiment: Management to present at multiple investor conferences in March (TD Cowen, Leerink, Jefferies, Barclays) — increases investor access but is informational rather than immediately value‑moving. BioMarin to Participate in Four Upcoming Investor Conferences in March
• Neutral Sentiment: Oppenheimer trimmed its price target slightly (from $98 to $95) but retained an Outperform rating — a modest signal that expectations were nudged lower but still above the stock’s current level. Benzinga
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (hemophilia gene therapy) from the market — a material setback for the company’s gene‑therapy franchise and a key reason for near‑term share weakness. BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
• Negative Sentiment: Mixed/unclear earnings metrics: while revenue beat estimates, reported EPS and some GAAP figures were reported inconsistently across outlets and some headlines flagged an EPS miss — and guidance language (2026 guidance excluding Amicus) leaves near‑term visibility uncertain. BioMarin Q4 Earnings / Conference Call

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.